Browsing Tag
Ryoncil
7 posts
Mesoblast (ASX: MSB; Nasdaq: MESO) CEO invests A$2.73m as Ryoncil growth shifts focus to execution
Mesoblast Chief Executive Silviu Itescu has paid A$2.73 million to increase his ownership, adding an alignment signal as Ryoncil sales and late-stage programs reshape the company.
Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout
Mesoblast has treated at least 300 patients in MSB-DR004, starting the final 12-month clock towards a mid-2027 readout and potential United States filing. The milestone strengthens execution visibility, but it does not provide new efficacy data.
Mesoblast stock gains as Ryoncil revenue hits US$115m in first launch year
Mesoblast Ryoncil revenue hits US$115m in its first launch year. Read how ASX:MSB’s biotech story is shifting from promise to sales.
Cats finally get a disease-modifying therapy candidate as Gallant pilot data clears the bar and FDA opens the fast lane
Gallant reports positive randomised trial data for feline osteoarthritis stem cell therapy and wins FDA expanded conditional approval eligibility. Read the full analysis.
Mesoblast (ASX: MSB) ramps up GVHD play with record Ryoncil revenue and fresh $125m credit line
Ryoncil sales surged 60 percent for Mesoblast in Q4. Read how its $125M refinancing plan could reshape capital efficiency and future cell therapy expansion.
FDA grants orphan drug exclusivity to Mesoblast’s Ryoncil for pediatric SR-aGvHD
Find out how Mesoblast's FDA approval for Ryoncil in pediatric SR-aGvHD sets a new benchmark in stem cell therapy and market exclusivity strategy.
Mesoblast issues shares to Osiris Therapeutics after FDA approval of Ryoncil
Mesoblast Limited, a pioneering biotechnology company listed on the Australian Securities Exchange (ASX:MSB), has announced the issuance of…